The global protein labeling market size was estimated at USD 1.28 billion in 2016. Increase in R&D spending pertaining to proteomic research and rise in adoption of bioengineering techniques are anticipated to influence market growth.
Increasing number of new product launches, along with updates to existing technologies, is projected to drive progress. Kits, reagents, and services for biorthogonal, in vivo, or in vitro labeling of targeted peptides are offered by major players. Reagents for protein labeling are provided depending on their use in the identification, detection, and analysis of proteins in diagnostics and research-based biological tests. The significance of reagents in almost every step of the workflow and easy availability in the market contributed to the higher revenue share of reagents in 2016.
The method is used in various biotechnological applications such as protein microarray, fluorescence microscopy, cell-based assays, mass spectroscopy, and immunological techniques for research and pharmaceutical diagnosis. Although research in the sector has been witnessing slow growth in the past, rise in industry spending is sure to have a positive impact.
Demand for highly specific and advanced technologies from end-users in the diagnostic pharmaceutical sector in the detection and purification of proteins of interest is expected to increase revenue generation over the forecast period. The development of diagnostic tests based on the detection of presence or absence of specific protein is of immense importance for diagnosis of diseases such as Ebola.
Technological advances in protein labeling in recent years is expected to boost revenue generation. For instance, MILLIPLEX MAP Equine Cytokine/Chemokine Panel was launched in May 2016. The product offers equine-specific multiplex assay for protein biomarkers with the ability to simultaneously measure about 27 cytokines in equine serum, cell culture supernatants, or plasma. Similar product launches have enhanced the research scope using such methods.
Prominently used reagents in protein labeling include proteins, enzymes, probes/tags, and monoclonal antibodies. Labeling techniques provide covalent attachment of different probe molecules such as reporter enzymes, biotin, and radioactive isotopes to the target protein. Increasing adoption in proteomic and genomic research and clinical diagnostics is expected to fuel demand for these reagents, thereby supporting the growth of this segment.
However, ready-to-use kits are to estimated witness fastest growth as they are a convenient means of labeling protein and antibodies. A large number of players offer kits that can be directly used in applications such as cell-based assays, western blotting, ELISA, and immunofluorescence. Introduction of kits that allow primary antibodies and proteins to be labeled within 20 minutes to develop rapid clinical tests and save time for research is expected to augment segment growth.
The services segment is projected to witness lucrative growth owing to increased outsourcing of technical and skilled workflow procedures.
Protein labeling is widely implemented in most immunological techniques such as flow cytometry, immunoassays, and immunofluorescence. These immunological assays are highly adopted in therapeutics, cancer research, autoimmune diseases, and endocrine diseases such as diabetes, rheumatoid arthritis, and pulmonary diseases. Lack of proper therapeutics to tackle chronic conditions is a key factor contributing to higher adoption of immunological techniques.
However, fluorescent protein labeling provides more specificity at lower concentrations compared to other methods. Various labeling and staining techniques and computer-controlled and laser confocal microscopy are being developed. Fluorescence microscopy is estimated to witness the fastest growth in the protein labeling market over the forecast period, registering a CAGR of 9.7%.
As a result of a considerable number of ongoing clinical investigation studies on proteomic analysis of genetic data, the in vitro method accounted for a larger revenue share in 2016. Higher usage in biological research using enzymes, dyes, and nanoparticles and advances in site-specific and co-translation labeling is expected to continue contributing to revenue growth.
Increasing popularity of nanoparticles and growing awareness among researchers about the significance of nanotechnology in biological studies drives the in vitro segment. Continuous introduction of inorganic nanoparticles such as quantum dots and novel fluorescent latex/silica nanobeads for protein labeling is expected to fuel revenue generation.
Other methods include chemical methods and a combination of in vitro and in vivo methods. Bioengineering research is expected to introduce improved techniques for protein labeling, thereby contributing to market progress.
North America dominated the global market with a 49.0% share in terms of revenue in 2016. Presence of key players and rise in spending on genomic and proteomic research pertaining to innovations in bioengineering technologies are major drivers for the market in this region. Increasing adoption in personalized medicine and genomic sequencing is projected to contribute toward the region’s growth in revenue throughout the forecast period.
Asia Pacific is projected to witness growth at a faster rate over the forecast period due to rise in healthcare expenditure and high investments in omics research in key developing nations such as China and India. Furthermore, development in Japan in various streams such as proteomics, cancer proteomics, immunodynamics, and structural genomics fuels growth in this region.
Key participants in the market include F. Hoffmann-La Roche AG; GE Healthcare Life Science; Promega Corporation; PerkinElmer Inc.; Merck Millipore; Thermo Fisher Scientific Inc.; Kirkegaard & Perry Laboratories (KPL); Eurogentec S.A.; New England Biolabs; and LI-COR Inc.
Major players are involved in the launch of novel products and acquisition and amalgamations of smaller emerging entities to strengthen their market position. Expanding geographic reach and enhancing product portfolio are some other strategies adopted by larger companies to increase their market share.
Base year for estimation
Actual estimates/Historical data
2013 - 2015
2016 - 2024
Revenue in USD Million & CAGR from 2016 to 2024
North America, Europe, Asia Pacific, Latin America, MEA
U.S., Canada, Germany, U.K., Japan, China, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the global protein labeling market report on the basis of product, application, labeling method, and region:
Product Outlook (Revenue, USD Million, 2013 - 2024)
Application Outlook (Revenue, USD Million, 2013 - 2024)
Protein micro assay
Labeling Method Outlook (Revenue, USD Million, 2013 - 2024)
Dye based labeling
Co translational labeling
Regional Outlook (Revenue, USD Million, 2013 - 2024)
Middle East & Africa
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.